학술논문
COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial.
Document Type
article
Author
Habtehyimer, Feben; Zhu, Xianming; Redd, Andrew; Gebo, Kelly; Abraham, Alison; Patel, Eshan; Laeyendecker, Oliver; Gniadek, Thomas; Fernandez, Reinaldo; Baker, Owen; Ram, Malathi; Currier, Judith; Fukuta, Yuriko; Gerber, Jonathan; Heath, Sonya; Meisenberg, Barry; Huaman, Moises; Levine, Adam; Shenoy, Aarthi; Anjan, Shweta; Blair, Janis; Cruser, Daniel; Hammitt, Laura; Kassaye, Seble; Mosnaim, Giselle; Patel, Bela; Paxton, James; Raval, Jay; Sutcliffe, Catherine; Abinante, Matthew; Oei, Kevin; Cluzet, Valerie; Cordisco, Marie; Greenblatt, Benjamin; Rausch, William; Shade, David; Gawad, Amy; Klein, Sabra; Pekosz, Andrew; Shoham, Shmuel; Casadevall, Arturo; Bloch, Evan; Hanley, Daniel; Tobian, Aaron; Sullivan, David; Forthal, Donald; Cachay, Edward
Source
Microbiology Spectrum. 12(1)
Subject
Language
Abstract
This study examined the role that cytokines may have played in the beneficial outcomes found when outpatient individuals infected with SARS-CoV-2 were transfused with COVID-19 convalescent plasma (CCP) early in their infection. We found that the pro-inflammatory cytokine IL-6 decreased significantly faster in patients treated early with CCP. Participants with COVID-19 treated with CCP later in the infection did not have the same effect. This decrease in IL-6 levels after early CCP treatment suggests a possible role of inflammation in COVID-19 progression. The evidence of IL-6 involvement brings insight into the possible mechanisms involved in CCP treatment mitigating SARS-CoV-2 severity.